Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27363 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Nico Gagelmann und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Busulfan, Hematopoietic Stem Cell Transplantation, Primary Myelofibrosis, Transplantation Conditioning. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
One key aspect of allogeneic hematopoietic cell transplantation (HCT) is pretransplant conditioning, balancing risk for relapse versus non‐relapse mortality. Conditioning regimens with different alkylators at different doses can influence outcome, but data are missing for myelofibrosis, a challenging cohort of patients usually presenting at older age and with comorbidities. We evaluated in a multicenter retrospective study the comparative efficacy and safety of busulfan versus treosulfan in combination with fludarabine for myelofibrosis patients undergoing HCT. This study included 1115 patients (busulfan, n = 902; treosulfan, n = 213) receiving first HCT between 2005 and 2021. Patients were generally balanced for key patient characteristics. Overall survival at 4 years was 62% for the busulfan group versus 58% for the treosulfan group ( p = .22). Impact on outcome was dose‐dependent. Overall survival was 65% (95% CI, 61%–69%) for reduced intensity busulfan versus 69% (95% CI, 54%–84%) for reduced intensity treosulfan, 53% (95% CI, 44%–63%) for higher intensity busulfan, and 55% (95% CI, 46%–63%) for higher intensity treosulfan. Incidence of relapse was similar across intensity groups. In multivariable analysis, the hazard for death (with reduced intensity busulfan as reference) was 0.88 (95% CI, 0.39–2.01) for reduced intensity treosulfan ( p = .77), 1.42 (95% CI, 0.96–2.10) for higher intensity busulfan (0.08), and 1.61 (95% CI, 1.14–2.26) for higher intensity treosulfan ( p = .006). In terms of non‐relapse mortality, comparison was not significantly different, while the hazard ratio for higher intensity treosulfan was 1.48 (95% CI, 0.98–2.23; p = .06). Here, we showed comparable outcomes and improved survival in myelofibrosis undergoing HCT with reduced intensity busulfan or treosulfan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
- German Registry for Stem Cell Transplantation, DRST, Ulm, Germany.
- Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University of Duisburg-Essen, Essen, Germany.
- Department of Internal Medicine I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
- Department of Medicine A, University Hospital of Münster, Münster, Germany.
- Medical Clinic, Charité University Medicine Berlin, Berlin, Germany.
ORCID-Profile: Nico Gagelmann, Gesine Bug
Zitieren
APA
Gagelmann, N., Schuh, C., Flossdorf, S., Kunadt, D., Stelljes, M., Blau, I. W., Brecht, A., Bethge, W., Schroeder, T., Wulf, G., Sala, E., Bug, G., Fleischhauer, K., Kröger, N., & German Registry for Stem Cell Transplantation, DRST (2024). Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.27363
Vancouver
Gagelmann N, Schuh C, Flossdorf S, Kunadt D, Stelljes M, Blau IW, et al. Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation. American Journal of Hematology. 2024. doi:10.1002/ajh.27363
BibTeX
@article{Gagelmann2024,
author = {Gagelmann, Nico and Schuh, Claudia and Flossdorf, Sarah and Kunadt, Desiree and Stelljes, Matthias and Blau, Igor W and Brecht, Arne and Bethge, Wolfgang and Schroeder, Thomas and Wulf, Gerald and Sala, Elisa and Bug, Gesine and Fleischhauer, Katharina and Kröger, Nicolaus and German Registry for Stem Cell Transplantation, DRST, German Registry for Stem Cell Transplantation, DRST},
title = {Impact of busulfan versus treosulfan dose intensity in myelofibrosis undergoing hematopoietic cell transplantation},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27363}
}
EUVIMED